

Pharmacy & Therapeutics Committee

Meeting Agenda

Thursday, May 16, 2024

7:00 a.m. to 8:45 a.m.

Google Meet joining information

Video call link: <https://meet.google.com/tni-wias-qke>

Or dial: (US) +1 413-259-8936 PIN: 592 159 502#

Persons who wish to address the P&T Committee may contact Bryan Larson at (bslarson@utah.gov) prior to the meeting or sign up to provide comments at the meeting. Public comments will be limited to 3 minutes per speaker or organization due to time constraints.

- 1) Call to order Cole Sloan, PharmD, Chair
 - a) Announce Quorum

- 2) Welcome and Introductions Cole Sloan, PharmD, Chair
 - a) Review and Approval of Minutes
 - b) Housekeeping
 - i) P&T Committee Bylaws updates Bryan Larson, PharmD

- 3) DUR Board Update Ngan Huynh, PharmD

- 4) Review Valerie Gonzales, PharmD
 - a) Anti-VEGF (Oral)
 - i) axitinib (Inlyta), cabozantinib (Cabometyx, Cometriq), fruquintinib (Fruzaqla), lenvatinib (Levinma), pazopanib (Votrient), regorafenib (Stivarga), sorafenib (Nexavar), sunitinib (Sutent), tivozanib (Fotivda), vandetanib (Calpresa)
 - b) Public Comment
 - c) Committee Discussion/Questions
 - d) Committee Action

- 5) Next Meeting Thursday, September 19, 2024: Hereditary Angioedema

- 6) Adjourned Cole Sloan, PharmD, Chair

Individuals with questions about accessibility or requesting special accommodations for this meeting should contact Bryan Larson at bslarson@utah.gov.

Pharmacy & Therapeutics Committee

Meeting Agenda

The foundation documents used for most reviews are prepared by the University of Utah, College of Pharmacy, and are posted on the P&T Committee website after the meeting. Manufacturers wishing to submit any additional materials they would like reviewed as part of the process to:

Dr. Joanne LaFleur
College of Pharmacy
30 South 2000 East
SLC, UT 84112-5820

All materials must be clearly labeled that they are submitted for consideration as part of the state of Utah Medicaid Preferred Drug List Program review process. Materials must be received at least 60 days before the scheduled review date. Materials most useful to support the evidence-based process include any new evidence (information from clinical trials or studies when possible), unpublished materials the company would like considered as part of the process, or any other materials not likely to be included in a literature search.

Tentative Upcoming Pharmacy & Therapeutics Committee Schedule

Month	Topic	Agents
19 Sep 2024	Hereditary Angioedema	<i>Berinert, Cinryze, Empaveli, Enjaymo, Firazyr, Haegarda, Kalbitor, Orladeyo, Ruconest, Sajazir, Soliris, Takhzyro, Tavneos, Ultomiris, Veopoz</i>
21 Nov 2024	Duchene Muscular Dystrophy	<i>deflazacort (Emflaza), vamorolone (Agamree), casimersen (Amondys 45), eteplirsen (Exondys 51), golodirsen (Vyondys 53), viltolarsen (Viltepso), delandistrogene moxeparvovec (Elevidys)</i>

Please note: all topics are tentative and subject to change.

Individuals with questions about accessibility or requesting special accommodations for this meeting should contact Bryan Larson at bslarson@utah.gov.